ATS To Promote Mechanical Heart Valves Over Tissue In Younger Patients
This article was originally published in The Gray Sheet
Executive Summary
ATS Medical will rely on an "indications-based" sales strategy, starting in the second half of 2005 to offset cardiac surgeons' increasing preference for tissue heart valves over mechanical valves
You may also be interested in...
Cryoablation Safer Than RF In Treating Atrial Fib, Trial Sponsor Says
CryoCath expects to learn by April whether FDA will require a follow-up period of longer than six months for a pivotal study of the Arctic Front ablation catheter to treat chronic atrial fibrillation
ATS Medical To Launch Open Pivot Bileaflet Heart Valve By Nov. 1
Shipments of ATS Medical's Open Pivot bileaflet mechanical heart valve, which received FDA approval Oct. 13, are scheduled to begin before month-end, the company says.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.